SEOM Clinical guidelines for the treatment of advanced colorectal cancer 2013

被引:0
作者
E. Casado-Saenz
J. Feliu
M. A. Gomez-España
A. Sanchez-Gastaldo
R. Garcia-Carbonero
机构
[1] Hospital Infanta Sofia,Medical Oncology Department
[2] Hospital La Paz,Medical Oncology Department
[3] Hospital Reina Sofia,Medical Oncology Department
[4] Hospital Universitario Virgen del Rocío,Servicio de Oncología Médica
[5] Instituto de Biomedicina de Sevilla (IBIS) [Universidad de Sevilla,undefined
[6] CSIC,undefined
[7] HUVR],undefined
来源
Clinical and Translational Oncology | 2013年 / 15卷
关键词
Colorectal cancer; Guidelines; Chemotherapy; Surgery;
D O I
暂无
中图分类号
学科分类号
摘要
Colorectal cancer (CRC) is the most common malignant tumor in Western countries. Despite efforts made to implement screening programmes for early detection and treatment, still half of the patients present or will eventually develop distant metastasis. Management of advanced CRC should be discussed within an experienced multidisciplinary team, to adequately select the most appropriate systemic therapeutic option, as well as the optimal way to integrate it with surgical procedures when indicated. Disease localization and extent, resectability of primary and metastatic disease, tumor biology and dynamics, clinical symptoms, personal preferences and patient’s ability to tolerate intensive chemotherapy or extensive surgical procedures are the key factors to properly design a customized treatment plan. The aim of the current manuscript is to provide synthetic practical guidelines regarding therapeutic options for advanced CRC.
引用
收藏
页码:996 / 1003
页数:7
相关论文
共 156 条
[1]  
Sánchez MJ(2010)Cancer incidence and mortality in Spain: estimates and projections for the period 1981–2012 Ann Oncol 21 iii30-766
[2]  
Payer T(2002)Trends in long-term survival following liver resection for hepatic colorectal metastases Ann Surg 235 759-657
[3]  
De Angelis R(2004)Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival Ann Surg 240 644-827
[4]  
Larrañaga N(2004)Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases Ann Surg. 39 818-1016
[5]  
Capocaccia R(2008)Perioperative chemotherapy with FOLFOX 4 and surgery versus surgery alone for resectable liver metastasis from colorectal cancer (EORTC Intergroup Trial 40983): A randomized control trial Lancet 371 1007-2947
[6]  
Martinez C(2000)Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2938-2069
[7]  
Choti MA(2003)Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial J Clin Oncol 21 2059-1047
[8]  
Sitzmann JV(2000)Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 1041-237
[9]  
Tiburi MF(2004)FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 229-1197
[10]  
Sumetchotimetha W(2004)Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials Br J Cancer 90 1190-1676